1.An adenosquamous carcinoma of the liver that developed metachronously in a patient with a colon adenocarcinoma.
Byoung Wook BANG ; Mie Jin LIM ; Joo Han LIM ; Eun Joo KIM ; Seok JEONG ; Suk Jin CHOI ; In Suh PARK
Korean Journal of Medicine 2007;72(1):74-78
A primary adenosquamous carcinoma of the liver is a rare subtype of a cholangiocarcinoma. Adenosquamous carcinoma is known to have an aggressive biologic behavior and is associated with a poor prognosis. Recently, we experienced a case of a primary adenosquamous carcinoma of the liver. A 69-year-old man was subjected to a right hemicolectomy five months ago due to an ascending colon cancer. At a periodic check-up, abdominal ultrasonography and magnetic resonance imaging showed a ~1.1 cm-sized hepatic mass which was highly suspicious of being a hepatic metastasis from the ascending colon cancer. A hepatic segmentectomy was performed. The tumor was microscopically composed of an adenocarcinoma and a squamous cell carcinoma, and it was different from the previous colon cancer as determined by immunohistochemistry. Three months after the hepatic segmentectomy, multiple hepatic metastasis was found and the patient has been treated as an outpatient with capecitabine.
Adenocarcinoma*
;
Aged
;
Carcinoma, Adenosquamous*
;
Carcinoma, Squamous Cell
;
Cholangiocarcinoma
;
Colon*
;
Colon, Ascending
;
Colonic Neoplasms
;
Humans
;
Immunohistochemistry
;
Liver*
;
Magnetic Resonance Imaging
;
Mastectomy, Segmental
;
Neoplasm Metastasis
;
Outpatients
;
Prognosis
;
Ultrasonography
;
Capecitabine
2.Palisaded Neutrophilic Granulomatous Dermatitis in a Patient with Systemic Sclerosis-Rheumatoid Arthritis Overlap Syndrome.
Kyong Hee JUNG ; Sangho JEONG ; Seong Ryul KWON ; Mie Jin LIM ; Jiyeon GWON ; Jeonghyun SHIN ; Won PARK
Annals of Dermatology 2017;29(6):804-806
No abstract available.
Arthritis*
;
Dermatitis*
;
Humans
;
Neutrophils*
3.Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use.
Mie Jin LIM ; Seong Ryul KWON ; Kowoon JOO ; Min Jung SON ; Shin Goo PARK ; Won PARK
The Korean Journal of Internal Medicine 2014;29(6):807-813
BACKGROUND/AIMS: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. METHODS: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). RESULTS: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARD-naive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 +/- 2.12 pg/mL at baseline to 2.51 +/- 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). CONCLUSIONS: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
Adult
;
Alkaline Phosphatase/blood
;
Arthritis, Rheumatoid/blood/diagnosis/*drug therapy
;
Biological Markers/blood
;
Bone Morphogenetic Proteins/blood
;
Bone Remodeling/*drug effects
;
Collagen Type I/blood
;
Female
;
Genetic Markers
;
Homeostasis
;
Humans
;
Immunoglobulin G/*administration & dosage
;
Immunosuppressive Agents/*administration & dosage
;
Inflammation Mediators/blood
;
Male
;
Middle Aged
;
Peptides/blood
;
Receptors, Tumor Necrosis Factor/*administration & dosage
;
Time Factors
;
Treatment Outcome
;
Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.Erratum: Correction of Title.
Kowoon JOO ; Won PARK ; Moon Hyun CHUNG ; Mie Jin LIM ; Kyong Hee JUNG ; Yoonseok HEO ; Seong Ryul KWON
Journal of Korean Medical Science 2013;28(3):493-493
This erratum is being published to correct of title.
5.Tumor Necrosis Factor Blockade Stimulates Circulating Osteoblastic Lineage Cells Activity while Reducing Circulating Osteoclasts.
Mie Jin LIM ; Seong Ryul KWON ; Kyong Hee JUNG ; Won PARK
Journal of Rheumatic Diseases 2016;23(6):356-362
OBJECTIVE: This study examines the effects of tumor necrosis factor (TNF) blockade on markers of bone metabolism in peripheral blood from active rheumatoid arthritis (RA) patients. METHODS: Eighteen patients (16 women, 2 men) aged 50 years (range 37-63 years), with persistently active RA (mean disease duration 7 years) were studied. Most took methotrexate (mean dose 12.5 mg) and all except one received corticosteroid (mean dose 5.7 mg). Four were treated with etanercept, eight received adalimumab and six received infliximab. Before and six months after taking TNF blockers, blood was sampled to obtain peripheral blood mononuclear cells (PBMCs), and serum bone turnover markers and acute phase reactants were measured. PBMCs were seeded and cultured to produce osteoblastic lineage cells and osteoclasts. RESULTS: The formation of calcified nodules by osteoblastic lineage cells from PBMC increased from 205.7±196.3 µmol/well at the baseline to 752.5±671.9 µmol/well after TNF blockade (p<0.024). The serum levels of bone formation markers, including bone specific alkaline phosphatase and osteocalcin also increased. The number of circulating osteoclasts and area of bone resorption pits made by osteoclasts were reduced after TNF blockade. CONCLUSION: The activity of circulating osteoblastic lineage cells increased after TNF blockade, whereas peripheral osteoclastogenesis tended to be suppressed. This is the first study of cultured human peripheral osteoblastic lineage cells in RA patients. Given that peripheral bone formation is difficult to study using radiologic methods, culture of these cells may provide a new modality for studying bone metabolism in RA.
Acute-Phase Proteins
;
Adalimumab
;
Alkaline Phosphatase
;
Arthritis, Rheumatoid
;
Biological Therapy
;
Bone Remodeling
;
Bone Resorption
;
Etanercept
;
Female
;
Humans
;
Infliximab
;
Metabolism
;
Methotrexate
;
Osteoblasts*
;
Osteocalcin
;
Osteoclasts*
;
Osteogenesis
;
Tumor Necrosis Factor-alpha*
6.The Osteoclast Development in Patients with Rheumatoid Arthritis and the Influence of the Bisphosphonate on Its Development.
Sung Soo KIM ; Seong Ryul KWON ; Mie Jin LIM ; Won PARK
The Journal of the Korean Rheumatism Association 2007;14(1):31-42
No Abstract available.
Arthritis, Rheumatoid*
;
Humans
;
Osteoclasts*
7.Serum Procalcitonin for Differentiating Bacterial Infection from Disease Flares in Patients with Autoimmune Diseases.
Kowoon JOO ; Won PARK ; Mie Jin LIM ; Seong Ryul KWON ; Jiyeol YOON
Journal of Korean Medical Science 2011;26(9):1147-1151
Early differentiation between bacterial infections and disease flares in autoimmune disease patients is important due to different treatments. Seventy-nine autoimmune disease patients with symptoms suggestive of infections or disease flares were collected by retrospective chart review. The patients were later classified into two groups, disease flare and infection. C-reactive protein (CRP) and serum procalcitonin (PCT) levels were measured. The CRP and PCT levels were higher in the infection group than the disease flare group (CRP,11.96 mg/dL +/- 9.60 vs 6.42 mg/dL +/- 7.01, P = 0.003; PCT, 2.44 ng/mL +/- 6.55 vs 0.09 ng/mL +/- 0.09, P < 0.001). The area under the ROC curve (AUC; 95% confidence interval) for CRP and PCT was 0.70 (0.58-0.82) and 0.84 (0.75-0.93), which showed a significant difference (P < 0.05). The predicted AUC for the CRP and PCT levels combined was 0.83, which was not significantly different compared to the PCT level alone (P = 0.80). The best cut-off value for CRP was 7.18 mg/dL, with a sensitivity of 71.9% and a specificity of 68.1%. The best cut-off value for PCT was 0.09 ng/mL, with a sensitivity of 81.3% and a specificity of 78.7%. The PCT level had better sensitivity and specificity compared to the CRP level in distinguishing between bacterial infections and disease flares in autoimmune disease patients. The CRP level has no additive value when combined with the PCT level when differentiating bacterial infections from disease flares.
Adult
;
Aged
;
Area Under Curve
;
Autoimmune Diseases/complications/*diagnosis
;
Bacterial Infections/complications/*diagnosis
;
C-Reactive Protein/analysis
;
Calcitonin/*blood
;
Female
;
Humans
;
Male
;
Middle Aged
;
Odds Ratio
;
Protein Precursors/*blood
;
ROC Curve
;
Retrospective Studies
;
Sensitivity and Specificity
8.Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy.
Kowoon JOO ; Seong Ryul KWON ; Mie Jin LIM ; Kyong Hee JUNG ; Hoyeon JOO ; Won PARK
Journal of Korean Medical Science 2014;29(5):657-661
The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients. We retrospectively reviewed patients who were diagnosed to have gout with at least 3 yr of follow up. They were divided into 2 groups; 53 patients with mean serum uric acid level (sUA)<6 mg/dL and 147 patients with mean sUA> or =6 mg/dL. Comorbidities of gout such as hypertension (HTN), type II diabetes mellitus (DM), chronic kidney disease, cardiovascular disease (CVD) and urolithiasis were compared in each group at baseline and at last follow-up visit. Frequency of acute gout attacks were also compared between the groups. During the mean follow up period of 7.6 yr, the yearly rate of acute attack and the new development of HTN, DM, CVD and urolithiasis was lower in the adequately treated group compared to the inadequately treated group. Tight control of uric acid decreases the incidence of acute gout attacks and comorbidities of gout such as HTN, DM, CVD and urolithiasis.
Adult
;
Allopurinol/therapeutic use
;
Antimetabolites/therapeutic use
;
Benzbromarone/therapeutic use
;
Cardiovascular Diseases/epidemiology/prevention & control
;
Comorbidity
;
Diabetes Mellitus, Type 2/epidemiology/prevention & control
;
Enzyme Inhibitors/therapeutic use
;
Female
;
Gout/*drug therapy/*prevention & control
;
Gout Suppressants/*therapeutic use
;
Humans
;
Hypertension/epidemiology/prevention & control
;
Male
;
Middle Aged
;
Renal Insufficiency, Chronic/epidemiology/prevention & control
;
Retrospective Studies
;
Thiazoles/therapeutic use
;
Uric Acid/*blood/metabolism
;
Uricosuric Agents/therapeutic use
;
Urolithiasis/epidemiology/prevention & control
9.Effects of Gout Web based Self-management Program on Knowledge Related to Disease, Medication Adherence, and Self-management.
Hyun Soo OH ; Won PARK ; Seong Ryul KWON ; Mie Jin LIM ; Yeon Ok SUH ; Wha Sook SEO ; Jong Suk PARK
Journal of Korean Academy of Nursing 2013;43(4):547-556
PURPOSE: This study was conducted to examine the changing patterns of knowledge related to disease, medication adherence, and self-management and to determine if outcomes were more favorable in the experimental group than in the comparison group through 6 months after providing a web-based self-management intervention. METHODS: A non-equivalent control group quasi-experimental design was used and 65 patients with gout, 34 in experimental group and 31 in comparison group, were selected from the rheumatic clinics of two university hospitals. Data were collected four times, at baseline, at 1 month, 3 months, and 6 months after the intervention. RESULTS: According to the study results, the changing patterns of knowledge and self-management were more positive in the experimental group than in the control group, whereas difference in the changing pattern of medication adherence between two groups was not significant. CONCLUSION: The results indicate that the web-based self-management program has significant effect on improving knowledge and self-management for middle aged male patients with gout. However, in order to enhance medication adherence, the web-based intervention might not be sufficient and other strategies need to be added.
Adult
;
Gout/*prevention & control
;
Health Knowledge, Attitudes, Practice
;
Hospitals, University
;
Humans
;
*Internet
;
Male
;
*Medication Adherence
;
Middle Aged
;
*Program Evaluation
;
*Self Care
;
User-Computer Interface
10.Erratum: Figure Correction.
Kowoon JOO ; Won PARK ; Mie Jin LIM ; Seong Ryul KWON ; Jiyeol YOON
Journal of Korean Medical Science 2011;26(11):1531-1531
No abstract available.